BIOVIA’s Post

🔬 Translational Medicine in Pharma & Biotech! 🌱 🌟 The top data challenge for Translational Medicine leaders: Integrating multi-omics data and clinical information to bridge the gap between research and patient care. 🔍 💡 Synthesizing genomics, proteomics, metabolomics, and clinical data is key to identifying biomarkers, understanding disease mechanisms, and predicting treatment outcomes in Translational Medicine. 🚀 🔬 Let's harness the power of data integration to accelerate the development of personalized therapies and enhance patient outcomes! 💪 #TranslationalMedicine #DataIntegration 🌐✨

🔬 Exciting Research from Our Chemistry Team at the School of Pharmacy, NGU! 🔬 We are thrilled to announce their latest publications in 2023. They have published 16 research papers highlighting the development of novel enzyme inhibitors to combat devastating diseases like Alzheimer's, cancer, and endometriosis, paving the way for potential therapeutic interventions. Moreover, they have utilized the power of artificial intelligence (AI) in the field of drug discovery. By integrating AI algorithms with cutting-edge bioanalysis techniques and pharmacokinetics, they are accelerating the identification and optimization of potential drug candidates. We are incredibly proud of our chemistry team's dedication, expertise, and invaluable contributions to scientific advancements. Their research is not only expanding our understanding of complex diseases but also bringing hope to countless individuals around the world. #ngu #whyngu #pleasureoflearning #ChemistryTeam #ResearchBreakthroughs #ScientificAdvancements #HealthcareInnovation #AlzheimersResearch #CancerResearch #EndometriosisResearch #DrugDiscovery #AIinScience #Bioanalysis #Pharmacokinetics

 🎖️Check out the Editor's Choice #Article "Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas" 👋by Vuong Trieu et al. Find the full paper here👉 https://lnkd.in/d66s7JBZ 🔹Since genome-wide data has become open to the public, many bioinformatics articles have been published which identified predictor genes or molecular targets in each malignant tumor. This article specified TGFB2 and IFN-γ as therapeutically targets, which can contribute to improve survival of the patients with low grade glioma.🔹

Nanopore sequencing and DNA barcoding methods give hope for personalized medicine. Researchers at Imperial College London, in collaboration with Oxford Nanopore Technologies, have developed a new diagnostic testing method that can analyze multiple types of biomarkers simultaneously. By examining proteins, small molecules, and miRNA molecules from the same clinical sample, this new method has the potential to revolutionize disease diagnosis, leading to more personalized medicine approaches and improved treatment options for patients. Read more: https://lnkd.in/gr7hBc_H #mirna #biomarker #medicine #lifescience #biology

"𝗣𝗵𝗲𝗻𝗼𝘁𝘆𝗽𝗶𝗰 𝗺𝗮𝗽𝘀" 𝗮𝘀 𝗮 𝘁𝗼𝗼𝗹 𝗳𝗼𝗿 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗺𝘂𝗹𝘁𝗶𝗼𝗺𝗶𝗰𝘀 𝗲𝗿𝗮 The reductionist approach to cancer research (and other complex diseases, for that matter) is gone. Omics technologies are here to stay, and great strides are being made to integrate diverse omics data sets. There is an obvious need to address the heterogeneity of diseases as it causes dramatic differences in the natural course of diseases as well as therapy responses. Questions remain, however, regarding the interpretability and translatability of those complex data sets. This paper describes an interesting approach of turning them into intuitive 2D maps. I found it interesting, and I hope you'll also find that perspective paper insightful. https://lnkd.in/djQHVCsv Full citation: Sayantan Bhattacharyya, Shafqat Ehsan and Loukia Karacosta (2023) Phenotypic maps for precision medicine: a promising systems biology tool for assessing therapy response and resistance at a personalized level. Front. Netw. Physiol. 3:1256104. doi: 10.3389/fnetp.2023.1256104. Paper and picture (taken from Figure 1) freely available under a Creative Commons license: https://lnkd.in/d72Y4gs6 #science #metabolism #omics #pharmacology #precisionmedicine

I found this article exemplifying a multiomics approach to phenotypic mapping for cancer very insightful, as it highlighted several advantages of a holistic vs reductionist systems biology approach to addressing the clinical needs of complex disease research and treatment. Precision medicine requires longitudinal assessment of dynamic genome, proteome, and metabolome patterns of change on a patient-by-patient basis. As I study Duchenne muscular dystrophy, this paper made me think of a recent article by L.G.M. Heezen et al in Pietro Spitali's lab at Leiden University Medical Center (https://lnkd.in/gbZfWwY7). The authors employed spatial transcriptomics and RNA velocity analysis to distinguish the cellular level transcriptomic landscape of skeletal muscle between healthy mice and two commonly studied DMD mouse models. This technological advance in DMD research could prove useful in differentiating disease progression for DMD (and related Becker muscular dystrophy) patients with distinct mutations in the Dmd gene, as well as in assessing therapeutic efficacy, particularly for exon-skipping, gene editing, and transgene delivery approaches that aim to restore functional dystrophin protein to dystrophic cells. Determining the tissue- and cell-specific localization of dystrophin expression in gene therapy-treated muscle, as well as using time course data to map dystrophin-replete vs dystrophin-deficient cells to defined phenotypic zones, would help address the ongoing concerns of limited dystrophin expression with current treatment strategies and provide an understanding of the optimal tissue microenvironment for maximal dystrophin expression. Such a phenotypic map would also provide a necessary benchmark for assessing therapeutic efficacy in preclinical and clinical trials.

💡Research Seminar || 19th June 2024, 10AM || MD9 Level 1 Workshop Room Registration Link: https://lnkd.in/g4CBJBHF Title: Novel regulatory mechanisms of PINK1, the guardian of mitochondria Han-Ming Shen: Mitophagy refers to a selective form of autophagy for clearance of damaged or dysfunctional mitochondria via the autophagy-lysosome pathway. PINK1 (PTEN-induced kinase 1) is a key Ser/Thr kinase that stabilizes and accumulates at mitochondria to initiate the mitophagy process, together with Parkin, an E3 ligase. Thus, PINK1 is considered as the guardian of mitochondria. In recent years, we have focused on PINK1, from its transcriptional regulation to its post-translational modifications (PTMs). First, we found that a specific autophagy inhibitor, Spautin-1, is capable of promoting mitophagy, mainly via promoting PINK1 stabilization and activation at outer mitochondrial membrane (OMM) by direct binding to the TOM complex. Second, we discovered O-GlcNAcylation as a novel form of PTMs in regulation of PINK1 stability and activity. Third, via both bioinformatics analysis and cellular-biochemical analysis, we identified SMAD3 as a novel nuclear transcriptional factor of PINK1, via a non-canonical pathway independent of TGF-b. Taken together, our work provides deeper insights into the molecular mechanisms of mitophagy and lays foundation for discovery of new interventional strategy for mitophagy-related human diseases such as neurodegenerative disorders.

The LightON mRNA💡🧬mRNA Biology Masterclass returns, in partnership with Endpoints News! This edition will explore the pivotal role that generating and analyzing large-scale mRNA biology data plays, providing the necessary foundation for leveraging AI technology. 📅 Join us on March 12th to hear from our speakers, Iris Alroy, Co-founder and CSO of Anima Biotech, and Gene Yeo, Professor of Cellular & Molecular Medicine at the University of California, as they delve into how AI can be applied to revolutionize our understanding of the complex mechanisms underlying mRNA regulation. 👉Register Today http://bit.ly/3SBCfjf #mRNABiology #ai #genomics #masterclass

🌟 So excited for this webinar! It's the first to delve into one of the most crucial aspects of our mRNA Biology-AI series: proprietary large-scale data. A huge thanks to our speakers and our partner Endpoints News. 🙌 Looking forward to bringing valuable insights to the scientific community. 💡